Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Vox Sanguinis

• Publication date

  2010-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1423-0410.2009.01264.xPMID 19821958
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune Skin Blistering Diseases

  2010cited by this paper
• Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial

  2009cited by this paper
• Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins.

  2009cited by this paper
• Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy

  2009cited by this paper
• Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

  2009cited by this paper
• Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease.

  2009cited by this paper
• Molecular mechanism and function of CD40/CD40L engagement in the immune system

  2009cited by this paper
• Immunosuppression of EAMG by IVIG Is Mediated by a Disease‐specific Anti‐immunoglobulin Fraction

  2008cited by this paper
• ITP three R's: regulation, routing, rituximab.

  2008cited by this paper
• Anti-inflammatory actions of intravenous immunoglobulin.

  2008cited by this paper
• Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses.

  2008cited by this paper
• Immunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal-regulated kinases 1 and 2.

  2008cited by this paper
• Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis.

  2008cited by this paper
• Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.

  2008cited by this paper
• IgG regulates the CD1 expression profile and lipid antigen-presenting function in human dendritic cells via FcgammaRIIa.

  2008cited by this paper
• Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc

  2008cited by this paper
• The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?

  2008cited by this paper
• Immunological Approaches for Amyloid-beta Clearance Toward Treatment for Alzheimer's Disease

  2008cited by this paper
• Intravenous immunoglobulin: adverse reactions and management.

  2008cited by this paper
• Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.

  2008cited by this paper
• Unlabeled uses of intravenous immune globulin.

  2008cited by this paper
• Use of intravenous immunoglobulin and plasma exchange in neurological disease

  2008cited by this paper
• The antiinflammatory IgG.

  2008cited by this paper
• Advances in the understanding of the mechanism of action of IVIg

  2008cited by this paper
• Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.

  2008cited by this paper
• What is the contents of the magic draft IVIg?

  2008cited by this paper
• Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations

  2008cited by this paper
• Intravenous immunoglobulins in the treatment of immune neuropathies

  2008cited by this paper
• The role of IVIg in autoimmune neuropathies: the latest evidence

  2008cited by this paper
• Plasma-derived biological medicines used to promote haemostasis

  2008cited by this paper
• Expert Opinion Regarding Clinical and Other Outcome Considerations in the Formulary Review of Immune Globulin

  2007cited by this paper
• Intravenous Immunoglobulin and Cytokines

  2007cited by this paper
• The use of i.v. IG therapy in dermatology

  2007cited by this paper
• Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura.

  2007cited by this paper
• Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti‐red blood cell antibodies in a mouse model of immune thrombocytopenic purpura

  2007cited by this paper
• Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade

  2007cited by this paper
• Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion.

  2007cited by this paper
• FcRn: the neonatal Fc receptor comes of age

  2007cited by this paper
• Hemostasis, Thrombosis, and Vascular Biology

  2007cited by this paper
• Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function

  2007cited by this paper
• Splenectomy in children with idiopathic thrombocytopenic purpura: A prospective study of 134 children from the Intercontinental Childhood ITP Study Group

  2007cited by this paper
• Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action

  2007cited by this paper
• A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?

  2007cited by this paper
• The antiinflammatory activity of IgG: the intravenous IgG paradox

  2007cited by this paper
• Adverse reactions and pathogen safety of intravenous immunoglobulin.

  2007cited by this paper
• The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model.

  2007cited by this paper
• Abnormality of CD4+CD25+ regulatory T cells in idiopathic thrombocytopenic purpura

  2006cited by this paper
• Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

  2006cited by this paper
• Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia

  2006cited by this paper
• Basic principles of intravenous immunoglobulin (IVIg) treatment

  2006cited by this paper
• Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells.

  2006cited by this paper
• Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema.

  2006cited by this paper
• Adverse events associated with intravenous immunoglobulin therapy.

  2006cited by this paper
• Childhood ITP: 12 months follow‐up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS)

  2006cited by this paper
• Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.

  2006cited by this paper
• Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells

  2006cited by this paper
• MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS)

  2005cited by this paper
• Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

  2005cited by this paper
• Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?

  2005cited by this paper
• Therapeutic intravenous immunoglobulins.

  2005cited by this paper
• Paths to understanding the genetic basis of autoimmune disease

  2005cited by this paper
• Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases.

  2005cited by this paper
• High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus.

  2005cited by this paper
• The Process: New Methods of Purification and Viral Safety

  2005cited by this paper
• Intravenous immunoglobulin and dendritic cells

  2005cited by this paper
• Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease

  2004cited by this paper
• CD40/CD154 interactions at the interface of tolerance and immunity.

  2004cited by this paper
• Thromboembolic Complications of Intravenous Immunoglobulin Treatment

  2004cited by this paper
• CD1: antigen presentation and T cell function.

  2004cited by this paper
• Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level.

  2004cited by this paper
• Natural antibodies sustain differentiation and maturation of human dendritic cells.

  2004cited by this paper
• Extended haplotypes and linkage disequilibrium in the IL1R1–IL1A–IL1B–IL1RN gene cluster: association with knee osteoarthritis

  2004cited by this paper
• Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin.

  2003cited by this paper
• Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding.

  2003cited by this paper
• The sympathetic nervous system is involved in variant Creutzfeldt-Jakob disease

  2003cited by this paper
• Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG.

  2003cited by this paper
• Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations.

  2003cited by this paper
• Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases

  2003cited by this paper
• F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins

  2003cited by this paper
• A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

  2003cited by this paper
• Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura.

  2003cited by this paper
• Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease.

  2003cited by this paper
• The clinical features of 16 cases of stroke associated with administration of IVIg

  2003cited by this paper
• Effect of High-Dose Intravenous Immunoglobulin Therapy in Stevens-Johnson Syndrome: A Retrospective, Multicenter Study

  2003cited by this paper
• Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases.

  2003cited by this paper
• Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy

  2003cited by this paper
• A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group.

  2003cited by this paper
• Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy.

  2002cited by this paper
• Intravenous Immunoglobulin Mediates an Increase in Anti-Platelet Antibody Clearance via the FcRn Receptor

  2002cited by this paper
• Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

  2002cited by this paper
• CD1 Molecules Efficiently Present Antigen in Immature Dendritic Cells and Traffic Independently of MHC Class II During Dendritic Cell Maturation1

  2002cited by this paper
• Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

  2002cited by this paper
• Historical Aspects and Present Knowledge of Idiopathic Thrombocytopenic Purpura

  2002cited by this paper
• No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment

  2002cited by this paper
• Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications.

  2002cited by this paper
• Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura.

  2002cited by this paper
• Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study.

  2001cited by this paper
• Polymorphisms in inflammatory cytokines and Fcγ receptors in childhood chronic immune thrombocytopenic purpura: a pilot study

  2001cited by this paper
• Emerging treatment for epidermolysis bullosa acquisita.

  2001cited by this paper
• Dendritic cells as vectors for therapy.

  2001cited by this paper

• Comparison of Ideal vs. Actual Body Weight Dosing of Intravenous Immunoglobulins for Immune Thrombocytopenia: A Retrospective Analysis

  2025cites this paper
• Glucocorticoid Resistance in Immune Thrombocytopenia: A Therapeutic Challenge or a Window for Precision Medicine?

  2025cites this paper
• Platelet Immune Interactions, Lifespan, and Senescence

  2025cites this paper
• Study on the influencing factors of the first-line treatment response to primary immune thrombocytopenia in children

  2025cites this paper
• Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system

  2022cites this paper
• Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease

  2022cites this paper
• Clinical Epidemiology, Treatment Outcome and Mortality Rate of Newly Diagnosed Immune Thrombocytopenia in Adult Multicentre Study in Malaysia

  2022cites this paper
• Immune Thrombocytopenia (ITP): Current Limitations in Patient Management

  2020cites this paper
• IVIg and hemolytic anemia risk: dump the anti‐A/B already!

  2020influential citation
• IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP.

  2020cites this paper
• Current perspective and scope of fetal therapy: part 2

  2020cites this paper
• [Guideline for diagnosis and treatment of immune thrombocytopenia].

  2019cites this paper
• Modulating the T Lymphocyte Immune Response via Secretome Produced miRNA: From Tolerance Induction to the Enhancement of the Anticancer Response

  2019cites this paper
• Manual of Intravenous and Subcutaneous IgG Indications in Autoimmune Diseases

  2018cites this paper
• Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases.

  2018cites this paper
• The potential association of tumor necrosis factor-βeta (252 G/A) cytokine gene polymorphism with immune thrombocytopenic purpura among Egyptian children

  2018cites this paper
• Immunomodulatory Drugs and Monoclonal Antibodies

  2018cites this paper
• Estudio del efecto sobre la hemostasia de los distintos agentes terapéuticos utilizados en el tratamiento de la trombocitopenia inmune

  2017cites this paper
• Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions

  2017cites this paper
• Thymic-derived tolerizing dendritic cells are upregulated in the spleen upon treatment with intravenous immunoglobulin in a murine model of immune thrombocytopenia

  2017cites this paper
• New aspects on the efficacy of high‐dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia

  2017cites this paper
• Inactivated pepsin inhibits neutrophil activation by Fcgamma-receptor-dependent and independent stimuli.

  2016cites this paper
• From immune substitution to immunomodulation.

  2016cites this paper
• 10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders.

  2016cites this paper
• Fetal and neonatal alloimmune thrombocytopenia.

  2016cites this paper
• Establishment of HSV1 Latency in Immunodeficient Mice Facilitates Efficient In Vivo Reactivation

  2015cites this paper
• Immunorégulation de la réaction du greffon contre l'hôte (GvHD) dans un modèle murin xénogénique : le rôle des immunoglobulines intraveineuses (IVIG)

  2015cites this paper
• Imuna trombocitopenija u djece

  2015cites this paper
• Mouse models of autoimmune diseases: immune thrombocytopenia.

  2015cites this paper
• The Use of Intravenous Immunoglobulins (IVIG) in Immunological Mediated Diseases and Possible Mechanisms of Actions

  2015cites this paper
• CD44 antibody–mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcγRIIb genetic disruption

  2015cites this paper
• Intravenous Immunoglobulins (IVIG) Enhance In vitro Activation of Neutrophils in C57BL/6 but not in CBA Mice

  2014cites this paper
• Role of Dendritic Cells in Autoimmunity in Aged Humans

  2014cites this paper
• Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study

  2014cites this paper
• Advances in the management of ITP in children and adults.

  2014cites this paper
• [Current treatment of primary immune thrombocytopenia].

  2014cites this paper
• Current Pathways for Immune Manipulation

  2014cites this paper
• Thrombopoietin receptor agonists in primary immune thrombocytopenia.

  2013cites this paper
• Cell death in immune thrombocytopenia: novel insights and perspectives.

  2013cites this paper
• The future of immunoglobulin therapy: an overview of the 2nd international workshop on natural antibodies in health and disease.

  2013cites this paper
• Intravenous immunoglobulin application in clinical practice

  2013influential citation
• Management of children and adolescents with primary immune thrombocytopenia: controversies and solutions

  2013cites this paper
• Применение внутривенных иммуноглобулинов в клинической практике

  2013cites this paper
• Intravenous immunoglobulin G (IVIg): Properties of dimeric and sialylated IgG

  2013cites this paper
• Suppression of PAMPs, Pathogen-Associated Microbial Patterns, Induced Cytokine Synthesis of PBMC, Human Blood Mononuclear Cells, by Immunoglobulin Preparation

  2012influential citation
• Acquired haemophilia A treated with Rituximab in a patient with prostatic melioidosis

  2012cites this paper
• Analysis and Functional Consequences of Increased Fab-Sialylation of Intravenous Immunoglobulin (IVIG) after Lectin Fractionation

  2012cites this paper
• The role of sialic acid as a modulator of the anti-inflammatory activity of IgG

  2012cites this paper
• Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review.

  2012cites this paper
• Influence of Intravenous Immunoglobulin Treatment on Thrombopoiesis

  2012cites this paper
• 30 years of immunomodulation by intravenous immunoglobulin.

  2012cites this paper
• Complete immunotolerance induction after FEIBA prophylaxis in a haemophilia A patient with high‐titre inhibitor

  2012cites this paper
• "Despite the difficulty in defining the multiple and complex mechanisms of action of intravenous immuno gobulin, this biological drug - be it transiently or for long‑term benefit - became essential for many patients ..."

  2012cites this paper
• Enrichment of Sialylated IgG by Lectin Fractionation Does Not Enhance the Efficacy of Immunoglobulin G in a Murine Model of Immune Thrombocytopenia

  2011cites this paper
• Current treatment options for primary immune

  2011cites this paper
• Current treatment options for primary immune thrombocytopenia

  2011cites this paper
• Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group

  2011cites this paper
• Oxidative stress may cause ITP.

  2011cites this paper
• Thrombopoietin-receptor agonists for primary immune thrombocytopenia.

  2011cites this paper
• C2 Plasma-derived immunoglobulins

  2011cites this paper
• When a Child with Immune Thrombocytopenia Experiences Life-threatening Bleeding

  2010cites this paper
• Mechanisms of action of intravenous immunoglobulins

  2010cites this paper
• [Guideline for diagnosis and treatment of immune thrombocytopenia].

  2010cites this paper
• To Gel or Not To Gel

  2009cites this paper
• Immunological Approaches for Amyloid-beta Clearance Toward Treatment for Alzheimer's Disease

  2008cites this paper